EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 71 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR Rucaparib Monotherapy Provides Significant and Durable Long-Term Benefit as First-Line Maintenance for Patients with Advanced Ovarian Cancer with and without HRD FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence MOST POPULAR Study Finds Disparities in Access to Opioids for Cancer Pain at... February 14, 2023 Tebentafusp Shows Promising Clinical Activity with an Acceptable Safety Profile in... October 17, 2022 Efficacy of Sintilimab in the Adjuvant Treatment for Patients with Resected,... January 26, 2024 Mom Of Two Diagnosed With Breast Cancer At 31: “I Just... February 28, 2020 Load more HOT NEWS The power of partnership – the unique alliance taking on brain... FDA Grants Accelerated Approval to Selpercatinib for Paediatric Patients Two Years... Happy Nurses Month! How Joining a Clinical Trial Helped Me Find Hope While Living...
